May 23, 2015
Below are current clinical trials.479 studies in Cancer
(open studies only).
Filter this list of studies by location, status and more.
The purpose of this study is to collect medical and family histories, blood and/or tumor tissue samples from patients who are being tested for or who have or had lung cancer. This study will help us to develop better ways to screen people at risk for lung cancer and develop better treatments for patients diagnosed with lung cancer. This study will also help us to learn whether certain genes (inherited factors from your parents) increase the risk of developing lung cancer.
Scottsdale/Phoenix, Ariz., Jacksonville, Fla., Rochester, Minn.
The purpose of this study is to profile and keep genetic sequencing from the bone marrow of patients who have multiple myeloma or another plasma cell malignancy. This will allow the comparing of genetic analysis with corresponding clinical information, for the purpose of identifying and applying disease biomarkers, for personalized treatments.
Introduction: Acute kidney injury (AKI) increases mortality, hospital cost, and rate of progression toward end stage kidney disease 1-4. Early diagnosis and management of AKI is known to improve the above mentioned outcomes.
Hypothesis: the investigators will design and validate an electronic surveillance tool to screen all the ICU admissions for the earlier, more efficient diagnosis of AKI and as a result improve the outcome of AKI in ICU patients.
Methods: the investigators plan to use the patient database, and AKIN (AKI network) definition to design an electronic alert system to allow clinicians discover patients who develop AKI. Then a randomized clinical trial will be conducted to compare earlier intervention (based on Kidney Disease: Improving Global Outcomes [KDIGO] guidelines) initiated by AKI sniffer alert to the conventional management provided by primary physician in ICU.
First study, at multiple clinical centers, exploring the effects of different combinations of compounds (CC-122, CC-223 ,CC-292 and rituximab) to treat Diffuse Large B Cell Lymphoma (DLBCL)
This phase II trial studies the side effects of erlotinib hydrochloride and how well it works in reducing duodenal polyp burden in patients with familial adenomatous polyposis at risk of developing colon cancer. Erlotinib hydrochloride may stop the growth of tumor cells by blocking some of the enzymes needed for cell growth.
The main purpose of this study is to evaluate the safety of a study drug known as LY2835219 in combination with different therapies (letrozole, anastrozole, tamoxifen, exemestane, exemestane plus everolimus, trastuzumab, or LY3023414 plus fulvestrant) for breast cancer that has spread to other parts of the body.
This phase I trial studies the side effects and best dose of paclitaxel albumin-stabilized nanoparticle formulation and bevacizumab in treating patients with stage IV melanoma that cannot be removed by surgery. Drugs used in chemotherapy, such as paclitaxel albumin-stabilized nanoparticle formulation, work in different ways to stop the growth of tumor cells, either by killing the cells or by stopping them from dividing. Monoclonal antibodies, such as bevacizumab, can block tumor growth in different ways. Some block the ability of tumor cells to grow and spread. Others find tumor cells and help kill them or carry tumor-killing substances to them. Giving paclitaxel albumin-stabilized nanoparticle formulation and bevacizumab many kill more tumor cells.
The purpose of this phase 1b/2 study is to evaluate a safe and tolerable recommended dose for TRC105 when added to standard dose sorafenib in patients with liver cell cancer, then to estimate the overall response rate.
The purpose of this study is to see if having different kinds of bacteria genes in breast tissue may be connected to the risk of getting breast cancer.
The purpose of this study is to assess the side effects and best dose of ruxolitinib phosphate when given together with pembrolizumab for treating patients with stage IV triple negative breast cancer that has spread to other places in the body. Monoclonal antibodies, such as pembrolizumab, may interfere with the ability of tumor cells to grow and spread. Ruxolitinib phosphate may stop the growth of tumor cells by blocking some of the enzymes needed for cell growth. Giving pembrolizumab and ruxolitinib phosphate together may work better in treating patients with stage IV triple negative breast cancer.
- Deaths and mortality. Centers for Disease Control and Prevention. http://www.cdc.gov/nchs/fastats/deaths.htm. Accessed April 23, 2015.
- Cancer: All sites. Surveillance Epidemiology and End Results. http://seer.cancer.gov/statfacts/html/all.html. Accessed April 23, 2015.
- Symptoms. National Cancer Institute. http://www.cancer.gov/cancertopics/diagnosis-staging/symptoms. Accessed April 23, 2015.
- Kushi LH, et al. American Cancer Society guidelines on nutrition and physical activity for cancer prevention: Reducing the risk of cancer with healthy food choices and physical activity. CA: A Cancer Journal for Clinicians. 2012;62:30.
- Niederhuber JE, et al., eds. Genetic and epigenetic alterations in cancer. In: Abeloff's Clinical Oncology. 5th ed. Philadelphia, Pa.: Churchill Livingstone Elsevier; 2014. http://www.clinicalkey.com. Accessed April 23, 2015.
- Ulcerative colitis. National Institute of Diabetes and Digestive and Kidney Diseases. http://digestive.niddk.nih.gov/ddiseases/pubs/colitis/index.htm. Accessed April 23, 2015.
- NINDS paraneoplastic syndromes information page. National Institute of Neurological Disorder and Stroke. http://www.ninds.nih.gov/disorders/paraneoplastic/paraneoplastic.htm. Accessed April 23, 2015.
- Deng GE, et al. Evidence-based clinical practice guidelines for integrative oncology: Complementary therapies and botanicals. Journal of the Society for Integrative Oncology. 2009;7:85.
- Taking time: Support for people with cancer. National Cancer Institute. http://cancer.gov/cancertopics/takingtime. Accessed April 23, 2015.
- Moynihan TJ (expert opinion). Mayo Clinic, Rochester, Minn. May 1, 2015.
- Hypercalcemia (high level of calcium in the blood). Merck Manual Home Edition. http://www.merckmanuals.com/home/hormonal-and-metabolic-disorders/electrolyte-balance/hypercalcemia-high-level-of-calcium-in-the-blood. Accessed April 23, 2015.
- What is cancer? National Cancer Institute. http://www.cancer.gov/cancertopics/what-is-cancer. Accessed April 23, 2015.
- Cancer prevention overview (PDQ). National Cancer Institute. http://www.cancer.gov/cancertopics/pdq/prevention/overview/patient/page1/AllPages. Accessed April 23, 2015.
- The genetics of cancer. National Cancer Institute. http://www.cancer.gov/cancertopics/causes-prevention/genetics. Accessed April 23, 2015.
- Understanding cancer risk. Cancer.Net. http://www.cancer.net/navigating-cancer-care/prevention-and-healthy-living/understanding-cancer-risk. Accessed April 23. 2015.
- Cancer screening overview (PDQ). National Cancer Institute. http://www.cancer.gov/cancertopics/pdq/screening/overview/HealthProfessional. Accessed April 23, 2015.
- Diagnosis. National Cancer Institute. http://www.cancer.gov/cancertopics/diagnosis-staging/diagnosis. Accessed April 23, 2015.
- Staging. National Cancer Institute. http://www.cancer.gov/cancertopics/diagnosis-staging/staging. Accessed April 23, 2015.
- Making decisions about cancer treatment. Cancer.Net. http://www.cancer.net/navigating-cancer-care/how-cancer-treated/making-decisions-about-cancer-treatment. Accessed April 23, 2015.
- How cancer is treated. Cancer.Net. http://www.cancer.net/navigating-cancer-care/how-cancer-treated. Accessed April 23, 2015.